

NOTICE TO THE BAR

MULTICOUNTY LITIGATION (MCL) – TERMINATION OF CENTRALIZED MANAGEMENT OF THE YAZ®, YAZMIN®, AND OCELLA® LITIGATION

In accordance with Court Rule 4:38A and the Multicounty Litigation Guidelines promulgated by Directive #8-12, a previous Notice to the Bar sought comments on the recommendation of Superior Court Judge Rachelle L. Harz for termination of the Multicounty Litigation (MCL) designation of the Yaz®, Yasmin®, and Ocella® Litigation. This Notice is to advise that the Supreme Court, after considering the recommendation and having received no comments, has terminated the MCL designation of all pending and future state-court litigation involving the oral contraceptives Yaz®, Yasmin®, and Ocella®.

Published with this Notice is the Court's January 29, 2019 Order. This Order is also posted on the Judiciary's Internet website (www.njcourts.gov) in the Multicounty Litigation Information Center (<https://www.njcourts.gov/attorneys/mcl/index.html>).

Questions concerning this action by the Court may be directed to Melissa Czartoryski, Esq., Chief, Civil Court Programs, Administrative Office of the Courts, Hughes Justice Complex, P.O. Box 981, Trenton, New Jersey 08625-0981; telephone (609) 815-2900 ext. 54900; email address: Melissa.Czartoryski@njcourts.gov.



Glenn A. Grant, J.A.D.
Acting Administrative Director of the Courts

Dated: February 6, 2019

SUPREME COURT OF NEW JERSEY

It is ORDERED that the Court's February 9, 2010 Order, as amended by Order dated July 22, 2016, designating all New Jersey state-court litigation involving the use of the drugs Yaz®, Yasmin®, and Ocella® as a mass tort (now multicounty litigation (MCL)) and assigning it to Bergen County (Vicinage 2) for centralized management, is hereby terminated.

For the Court,



Chief Justice

Dated: January 29, 2019